Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENYLBUTAZONE vs ACETAMINOPHEN AND IBUPROFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Relief of pain and inflammation in ankylosing spondylitis,Acute gouty arthritis,Osteoarthritis,Rheumatoid arthritis (short-term management),Off-label: Use in veterinary medicine for musculoskeletal disorders
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
Terminal elimination half-life is 50–65 hours, but exhibits dose-dependent kinetics; can extend to 72–100 hours with repeated dosing or in elderly.
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Hepatic metabolism via CYP2C9 and CYP3A4; major metabolite is oxyphenbutazone; minor pathways include hydroxylation and glucuronidation.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Primarily hepatic metabolism; renal excretion of metabolites (<1% unchanged). Biliary/fecal excretion accounts for ~20% of total elimination.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
98–99% bound, primarily to albumin.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
0.05–0.1 L/kg, indicating limited extravascular distribution; increased in hypoalbuminemia.
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
Oral: 100% absorbed, though systemic availability may be reduced by first-pass metabolism (bioavailability ~90%). Intramuscular: near 100%.
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
GFR 10-50: use 50% of normal dose. GFR <10: contraindicated due to accumulation of active metabolite oxyphenbutazone.
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated due to risk of hepatotoxicity.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
Not recommended in children under 14 years due to risk of Reye-like syndrome and hypersensitivity; safety and efficacy not established.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
Initiate at lowest effective dose (100 mg once or twice daily); monitor closely for fluid retention, GI bleeding, and renal impairment; avoid long-term use.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
WARNING: Aplastic anemia, agranulocytosis, and other blood dyscrasias have been associated with phenylbutazone. Use only when other NSAIDs have failed due to serious adverse effects. Monitor blood counts regularly. Risk is dose-related and increased with prolonged use.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Risk of bone marrow suppression (aplastic anemia, agranulocytosis); gastrointestinal ulceration and bleeding; renal toxicity (especially in elderly, dehydrated, or those with pre-existing renal impairment); hepatic dysfunction; hypersensitivity reactions; sodium and water retention; increased cardiovascular risk; use lowest effective dose for shortest duration.
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Hypersensitivity to phenylbutazone or other NSAIDs; history of aplastic anemia or agranulocytosis; active peptic ulcer disease; severe renal or hepatic impairment; advanced age; concomitant use with other NSAIDs or anticoagulants; pregnancy (third trimester) and lactation.
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Avoid taking with alcohol as it may increase the risk of gastrointestinal bleeding and hepatotoxicity. Grapefruit juice may increase drug levels and toxicity; avoid concurrent consumption. High-fat meals can delay but do not significantly reduce absorption; take with food or milk to minimize gastrointestinal irritation. Maintain adequate hydration unless contraindicated due to fluid retention concerns.
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
First trimester: Increased risk of cardiovascular malformations and neural tube defects due to inhibition of prostaglandin synthesis. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Avoid in all trimesters unless absolutely necessary.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Excreted into breast milk in low concentrations. M/P ratio is approximately 0.1–0.2. Potential for adverse effects in the infant, including platelet dysfunction and renal impairment. Avoid breastfeeding during therapy.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
Increased renal clearance and volume of distribution in pregnancy may reduce serum drug levels. However, due to significant teratogenic and fetal risks, use is contraindicated in pregnancy. No dosing adjustment justified.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) with potent anti-inflammatory, antipyretic, and analgesic effects, but its use is severely limited due to high risk of serious adverse effects including agranulocytosis, aplastic anemia, and hepatotoxicity. It is reserved for short-term treatment of severe conditions such as ankylosing spondylitis, acute gouty arthritis, and acute exacerbations of rheumatoid arthritis when other therapies are ineffective or contraindicated. Due to its long half-life (50-100 hours), dosing should be carefully adjusted, and complete blood counts (CBC) and liver function tests must be monitored regularly. It inhibits prostaglandin synthesis and can cause sodium and water retention, exacerbating hypertension and heart failure. Avoid concomitant use with other NSAIDs, anticoagulants, or methotrexate due to increased bleeding risk and toxicity.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Take this medication exactly as prescribed; do not exceed the recommended dose or duration of therapy due to risk of serious side effects.,Report any signs of infection (fever, sore throat, mouth ulcers), unusual bleeding or bruising, skin rash, or jaundice immediately.,Avoid alcohol and aspirin-containing products while taking this drug.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Use effective contraception if you are of childbearing age; this drug may be harmful to an unborn baby and should not be used in late pregnancy.,Do not take this drug with other NSAIDs (e.g., ibuprofen, naproxen) or corticosteroids without consulting your doctor.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
"The combination of fenoprofen, a nonsteroidal anti-inflammatory drug (NSAID), with phenylbutazone, another NSAID with potent anti-inflammatory effects, significantly increases the risk of gastrointestinal (GI) adverse effects, including ulceration, bleeding, and perforation. This additive toxicity arises from synergistic inhibition of cyclooxygenase (COX) enzymes, leading to reduced gastroprotective prostaglandin synthesis and impaired platelet aggregation. Clinically, patients may experience increased incidence of gastric mucosal injury, occult blood loss, and potentially life-threatening GI bleeding, particularly in elderly or renally impaired individuals."
"Aprepitant, a moderate CYP3A4 inducer, can accelerate the metabolism of Phenylbutazone, a nonsteroidal anti-inflammatory drug (NSAID) primarily metabolized by CYP3A4 and CYP2C9. This leads to reduced plasma concentrations of Phenylbutazone, potentially diminishing its analgesic and anti-inflammatory efficacy. The interaction may result in inadequate symptom control in patients with chronic inflammatory conditions such as rheumatoid arthritis."
"Phenylbutazone, a nonsteroidal anti-inflammatory drug (NSAID) with potent prostaglandin synthesis inhibition, antagonizes the vasodilatory and antiplatelet effects of epoprostenol, a prostacyclin analog. This occurs because phenylbutazone reduces the production of endogenous prostacyclin and may also compete for receptor binding or downstream signaling, thereby diminishing epoprostenol's therapeutic efficacy in pulmonary arterial hypertension. Clinically, this interaction may lead to increased pulmonary vascular resistance, worsening symptoms, and elevated risk of thrombotic events."
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENYLBUTAZONE vs ACETAMINOPHEN AND IBUPROFEN, answered by our medical review team.
PHENYLBUTAZONE is a NSAID that works by Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.. ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENYLBUTAZONE and ACETAMINOPHEN AND IBUPROFEN depend on the specific clinical indication. These are both NSAID agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENYLBUTAZONE is: Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.. The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining PHENYLBUTAZONE and ACETAMINOPHEN AND IBUPROFEN. The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibuprofen. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. PHENYLBUTAZONE is classified as Category C. First trimester: Increased risk of cardiovascular malformations and neural tube defects due to inhibition of prostaglandin synthesis. Second and third trimesters: Risk of premature. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.